Regenxbio outlines potential accelerated approval path for RGX-202 in 2027 following pivotal Phase III primary endpoint result (NASDAQ:RGNX)

REGENXBIO Q1 2026 earnings call: RGX-202 pivotal Duchenne data hit endpoint, SAEs manageable, 2027 accelerated approval target, $100M AbbVie.